Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,440 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06976762Enrolling by invitation
Light-based muscle oxygen measurements in COPD with kidney disease
This study uses a special light-based device (near-infrared spectroscopy) to measure muscle oxygen levels in people who have both COPD and chronic kidney disease. Researchers want to see if these measurements can help predict how the disease progresses, which could lead to better monitoring and treatment.
Tokat ProvinceAges 18–80 - NCT06981442Recruiting
Mosquito control study in Kinshasa
This trial looks at different ways to control mosquitoes that spread diseases. It will see how well these methods work in households and health facilities in Kinshasa.
Kinshasa, République Démocratique Du CongoAges 18 years+ - NCT06981637RecruitingPhase 2
PLD vs. observation for advanced soft tissue sarcoma
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
Kaohsiung CityAges 18 years+ - NCT06976437RecruitingEarly Phase 1
Testing donor CAR-T cells for B-cell blood cancers
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
Zhenjiang, JiangsuAges 18 years+ - NCT06969612RecruitingPhase 1
New drug combo as first treatment for advanced lung cancer
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03298334RecruitingPhase 1/Phase 2
Testing vaginal bacteria transfer to newborns after C-section
This study looks at whether they can safely place “healthy vaginal bacteria” from the mother into the newborn after a scheduled C-section, and whether it improves the baby’s health. It only enrolls certain mothers and babies based on infection testing and other health factors.
Falls Church, VirginiaAges birth–50 years - NCT05642858Recruiting
Learn heart health tips for people living with HIV
This study tests a text-message education program to help people living with HIV manage cardiovascular (heart and blood vessel) health. It may be helpful if you are 40 or older and can use a smartphone to receive messages.
San Francisco, CaliforniaAges 40 years+ - NCT06063681RecruitingPhase 1
Testing a new ENPPI inhibitor for advanced solid tumors
This trial tests a new drug, SR-8541A, that blocks an enzyme called ENPPI, which may help slow or stop tumor growth. It is for people with advanced or metastatic solid tumors who have not responded to other treatments or have no standard options.
Randwick, New South WalesAges 18 years+ - NCT06870630Recruiting
Comparing two myotomy methods for type 2 achalasia
This trial tests two muscle-cutting procedures for people newly diagnosed with type 2 achalasia (a swallowing disorder). The goal is to see if a more complex myotomy works better than the standard one.
Hyderabad, TelanganaAges 18–75 - NCT06966284Recruiting
Study Comparing Two Antibiotics for Resistant Infections
This study looks at two strong antibiotics, polymyxin B and colistin, given through a vein to treat serious infections like pneumonia or blood infections caused by bacteria that are resistant to many other antibiotics. The goal is to see how well they work and how safe they are.
TaipeiAges 18 years+ - NCT06963281RecruitingPhase 1
Study of an experimental drug for late-stage solid tumors
This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.
Phoenix, ArizonaAges 18–75 - NCT06967311Recruiting
What causes IBD flare-ups?
This study looks at how your body and gut germs may trigger flare-ups of inflammatory bowel disease (IBD). It may help doctors understand and predict when symptoms come back.
Florianópolis, Santa CatarinaAges 18 years+ - NCT06966700RecruitingPhase 3
Study of Sac-TMT in Early High-Risk Breast Cancer
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT06962865RecruitingPhase 2
RC108 and Furmonertinib for first-line treatment of EGFR-mutated and MET-positive NSCLC
This trial tests whether a combination of two drugs, RC108 and Furmonertinib, can help people with non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutation and MET positivity) and cannot be removed by surgery. It is for people who have not yet received treatment for their advanced or metastatic cancer.
BeijingAges 18–75 - NCT06962345Recruiting
Testing a new vaginal gel for menopause symptoms
This trial is testing a new non-hormonal gel for vaginal dryness and discomfort after menopause. It aims to see if the gel improves quality of life.
Madrid, MadridAges 40–70 - NCT06970639RecruitingPhase 3
Study comparing new targeted drug plus chemo vs osimertinib for lung cancer with brain tumors
This trial tests a new targeted therapy called furmonertinib combined with chemotherapy against the current standard osimertinib for people with a specific type of non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to find a better treatment option for patients whose cancer cells have a common EGFR mutation.
Guangdong, GuangzhouAges 18 years+ - NCT06971939RecruitingPhase 4
Long-term safety of NT-501 implant for MacTel type 2
This study checks the long-term safety and effectiveness of the NT-501 implant for people with MacTel type 2. It is for people who have already been in an earlier NT-501 study, whether they got the real implant or a sham procedure.
La Jolla, CaliforniaAges 18 years+ - NCT06965582Enrolling by invitation
Pulsed field ablation for enlarged prostate (BPH)
This trial tests a new device that uses pulsed electric fields to shrink an enlarged prostate (benign prostatic hyperplasia, or BPH). It's for men who have tried medication but still have bothersome symptoms.
BrnoAges 45 years+ - NCT06972446RecruitingPhase 2
Targeted therapies for rheumatoid arthritis
This study tests different targeted treatments for adults with rheumatoid arthritis who have already tried other biologic or targeted medications and need a new option. It aims to find which treatment works best for people like you.
Peoria, ArizonaAges 18 years+ - NCT06963814RecruitingPhase 1
HC006 with a PD-1 inhibitor for advanced solid tumors
This trial tests a new drug called HC006 combined with a standard immunotherapy (PD-1 inhibitor) for people with advanced solid tumors. It aims to see if the combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06969430RecruitingPhase 1/Phase 2
Debio 1562M for relapsed or refractory AML
This trial tests a new drug called Debio 1562M for people with AML that has not responded to treatment or has come back. It aims to see if the drug is safe and can help fight the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT06971614RecruitingPhase 2
T3011 for bladder cancer not responding to standard treatments
This trial tests a drug called T3011 for a type of bladder cancer that hasn't responded to standard treatments like BCG or chemotherapy. It aims to see if T3011 can help shrink the cancer or keep it from growing, offering a new option for people who have limited choices.
Queen Creek, ArizonaAges 18 years+ - NCT06962787RecruitingPhase 2
Study of BL-B01D1 + TKI with or without pembrolizumab for advanced kidney cancer
This trial is testing a new drug combination for people with advanced kidney cancer. The main drug, BL-B01D1, is given together with a targeted therapy (TKI) and sometimes also with an immunotherapy drug (pembrolizumab). The goal is to see if this combination can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06962696Recruiting
Testing AI to check home safety for older adults
This trial uses a smart computer program (GPT-4o) to check the safety of your home environment and see if it's safe for older adults. It's designed for seniors who live at home and can communicate easily.
Beijing, Beijing MunicipalityAges 65 years+
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,440 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.